Virbac SA: Business Overview, Financials & Competitive Analysis
Virbac SA scores 7/10 on the AskCyborg Cyborg Score (Strong). Strong incumbent in global animal health with attractive growth tailwinds from companion animal demand and strategic M&A capability. Virbac demonstrates solid fundamentals with consistent double-digit revenue growth, a leading market position as the 6th largest veterinary pharmaceutical company, and strong profitability metrics. Recent leadership transition and global diversification provide growth.
What is Virbac SA's industry? Virbac SA (corporate.virbac.com) operates in Veterinary Pharmaceuticals & Animal Health. AskCyborg classifies Virbac SA under Veterinary Pharmaceuticals & Animal Health in its company registry.
Virbac is a French company dedicated to animal health located in Carros, near Nice. The company is the 6th largest veterinarian pharmaceutical group with a turnover of 1,397 million euros in 2024 (62% companion animal...
Cyborg Score thesis
Strong incumbent in global animal health with attractive growth tailwinds from companion animal demand and strategic M&A...
Read the full analyst-debate transcript →Get the Latest Virbac SA Report
Up-to-date AI-powered research, analyst debate audio & saved-company playlists
Get Current Report FreeVirbac SA Overview
Pro stress-test →Virbac is a French company dedicated to animal health located in Carros, near Nice. The company is the 6th largest veterinarian pharmaceutical group with a turnover of 1,397 million euros in 2024 (62% companion animal and 38% food producing animal). The company serves a global customer base including veterinarians, farmers, and pet owners across multiple continents.
Strategic Profile
Pro stress-test →Virbac manufactures and sells a range of products and services for companion and farm animals globally, offering vaccines, antibiotics, parasiticides, and anti-inflammatory drugs, as well as dermatology, dental, specialty, diagnosis, nutrition, petfood, and pharmaceutical products. In 2024, Virbac's revenue was 1.40 billion, an increase of 12.07% compared to the previous year's 1.25 billion.
Competitive Landscape
Pro stress-test →Virbac is one of the 10 biggest veterinary pharmaceutical companies in the world. The company competes in the fragmented animal health sector alongside multinational pharma players with veterinary divisions and specialized animal health companies. Strong regional presence in Europe and Latin America provides competitive advantage alongside global scale competitors.
Industry Context
Virbac SA operates in Veterinary Pharmaceuticals & Animal Health.
Key facts
Founded: 1968 · Headquarters: Carros, France · Revenue: $1.40B · Market cap: $3.62B